AU2013234046B2 - Methods and compositions for modulating Toso activity - Google Patents

Methods and compositions for modulating Toso activity Download PDF

Info

Publication number
AU2013234046B2
AU2013234046B2 AU2013234046A AU2013234046A AU2013234046B2 AU 2013234046 B2 AU2013234046 B2 AU 2013234046B2 AU 2013234046 A AU2013234046 A AU 2013234046A AU 2013234046 A AU2013234046 A AU 2013234046A AU 2013234046 B2 AU2013234046 B2 AU 2013234046B2
Authority
AU
Australia
Prior art keywords
toso
soluble
protein
seq
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013234046A
Other languages
English (en)
Other versions
AU2013234046A1 (en
Inventor
Dirk Brenner
Karl Lang
Philipp Lang
Gloria Lin
Tak W. Mak
Pamela S. Ohashi
Michael W. Tusche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Original Assignee
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network filed Critical University Health Network
Publication of AU2013234046A1 publication Critical patent/AU2013234046A1/en
Application granted granted Critical
Publication of AU2013234046B2 publication Critical patent/AU2013234046B2/en
Priority to AU2017272172A priority Critical patent/AU2017272172B2/en
Priority to AU2019204594A priority patent/AU2019204594B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
AU2013234046A 2012-03-16 2013-03-14 Methods and compositions for modulating Toso activity Ceased AU2013234046B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2017272172A AU2017272172B2 (en) 2012-03-16 2017-12-05 Methods and compositions for modulating toso activity
AU2019204594A AU2019204594B2 (en) 2012-03-16 2019-06-28 Methods and compositions for modulating toso activity

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261612183P 2012-03-16 2012-03-16
US61/612,183 2012-03-16
US201261646143P 2012-05-11 2012-05-11
US61/646,143 2012-05-11
US201261731428P 2012-11-29 2012-11-29
US61/731,428 2012-11-29
PCT/IB2013/001179 WO2013136193A2 (en) 2012-03-16 2013-03-14 Methods and compositions for modulating toso activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017272172A Division AU2017272172B2 (en) 2012-03-16 2017-12-05 Methods and compositions for modulating toso activity

Publications (2)

Publication Number Publication Date
AU2013234046A1 AU2013234046A1 (en) 2014-10-09
AU2013234046B2 true AU2013234046B2 (en) 2017-09-07

Family

ID=48747619

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013234046A Ceased AU2013234046B2 (en) 2012-03-16 2013-03-14 Methods and compositions for modulating Toso activity
AU2017272172A Ceased AU2017272172B2 (en) 2012-03-16 2017-12-05 Methods and compositions for modulating toso activity
AU2019204594A Expired - Fee Related AU2019204594B2 (en) 2012-03-16 2019-06-28 Methods and compositions for modulating toso activity

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2017272172A Ceased AU2017272172B2 (en) 2012-03-16 2017-12-05 Methods and compositions for modulating toso activity
AU2019204594A Expired - Fee Related AU2019204594B2 (en) 2012-03-16 2019-06-28 Methods and compositions for modulating toso activity

Country Status (9)

Country Link
US (5) US9228006B2 (https=)
EP (2) EP2825191B1 (https=)
JP (3) JP6200437B2 (https=)
KR (1) KR102143887B1 (https=)
CN (1) CN104394880B (https=)
AU (3) AU2013234046B2 (https=)
CA (1) CA2867444C (https=)
IL (1) IL234683B (https=)
WO (1) WO2013136193A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2867444C (en) 2012-03-16 2021-04-13 University Health Network Compositions containing soluble toso protein and uses thereof
US9493561B2 (en) 2013-07-03 2016-11-15 University Health Network Antibodies to Toso
ES2795727T3 (es) * 2014-01-15 2020-11-24 Medimmune Llc Anticuerpos específicos del vrs y partes funcionales de los mismos
AU2015225867B2 (en) * 2014-03-07 2020-02-06 University Health Network Methods and compositions for modifying the immune response
EP3009841A1 (en) * 2014-10-14 2016-04-20 Bernhard-Nocht-Institut für Tropenmedizin Detection of IgM Antibodies using an immune complex (IC) ELISA
ES2754432T3 (es) 2015-05-04 2020-04-17 Apogenix Ag Proteínas agonistas de receptor CD40 de cadena sencilla
ES2690420T3 (es) * 2015-05-28 2018-11-20 Universität Zu Köln Receptor de antígeno quimérico anti-toso y su uso
CA3126295A1 (en) 2019-01-18 2020-07-23 University Health Network Lilrb3-binding molecules and uses therefor
MX2021009767A (es) * 2019-02-15 2021-11-17 Univ Health Network Moleculas de union de fmcr y usos de las mismas.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727350B2 (en) * 1997-11-17 2004-04-27 The Board Of Trustees Of The Leland Stanford Junior University Toso

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE229046T1 (de) 1985-03-30 1987-12-17 Marc Genf/Geneve Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2100892T3 (es) * 1989-09-15 1997-07-01 Tanox Biosystems Inc Tratamiento de enfermedades autoinmunitarias.
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5686073A (en) 1990-05-23 1997-11-11 The University Of Iowa Research Foundation Polyclonal and monoclonal antibodies against a 43 KDA dystrophin associated protein
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
RU2212899C2 (ru) 1991-09-13 2003-09-27 Чирон Корпорейшн Hcv иммунореактивные полипептидные композиции
JPH07501694A (ja) * 1991-11-18 1995-02-23 タノックス　バイオシステムズ　インコーポレイテッド 免疫グロブリン生産のアイソタイプ特異的抑制のためのアンチセンスオリゴヌクレオチド
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6709659B1 (en) 1996-08-02 2004-03-23 Zymogenetics, Inc. Antibodies that bind testis-specific insulin homolog polypeptides
US6555314B1 (en) * 1998-03-30 2003-04-29 Rigel Pharmaceuticals, Inc. Toso as a target for drug screening
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6683168B1 (en) 1998-04-21 2004-01-27 Boston Medical Center Corporation Genes and methods that modulate apoptosis
US6322788B1 (en) 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
CN1367688A (zh) * 1999-04-14 2002-09-04 美国政府卫生与公众服务部 用于诱导对移植物的免疫耐受性的、包含免疫毒素和抑制树突细胞成熟的因子的组合物
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
NZ521437A (en) * 2000-02-25 2004-04-30 Immunex Corp Integrin antagonists suitable as inhibitors of angiogenesis
ATE549347T1 (de) 2000-09-08 2012-03-15 Schering Corp Gene von säugetiere, und damit verbundene reagentien, methoden
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
CA2424977C (en) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
EP2322200A3 (en) * 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
WO2006071200A2 (en) 2004-12-30 2006-07-06 Agency For Science, Technology And Research Chinese hamster apoptosis-related genes
US7119179B1 (en) 2005-03-21 2006-10-10 Los Alamos National Security, Llc Preparation of high nitrogen compound and materials therefrom
JP2010502221A (ja) 2006-09-08 2010-01-28 アンブルックス，インコーポレイテッド 脊椎動物細胞による非天然アミノ酸の部位特異的組み込み
US8748379B2 (en) * 2007-06-06 2014-06-10 Research Development Foundation RTEF-1 variants and the use thereof for inhibition of angiogenesis
HUE028784T2 (en) * 2008-05-01 2017-01-30 Zymogenetics Inc Serum levels and use of BLYS / APRIL heterotrimers in diagnostic procedures
US20120148581A1 (en) 2009-08-17 2012-06-14 The Regents Of The University Of California Use of nkg2d inhibitors for treating cardiovascular and metabolic diseases, such as type 2 diabetes
CA2867444C (en) 2012-03-16 2021-04-13 University Health Network Compositions containing soluble toso protein and uses thereof
US11392902B2 (en) 2017-06-06 2022-07-19 United Parcel Service Of America, Inc. Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727350B2 (en) * 1997-11-17 2004-04-27 The Board Of Trustees Of The Leland Stanford Junior University Toso

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AGGARWAL AMITA ET AL, ARTHRITIS & RHEUMATISM, & 75TH ANNUAL SCIENTIFIC MEETING OF THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY/46TH ANNUAL SCIENTIFIC MEETIN; CHICAGO, IL, USA; NOVEMBER 04 -09, 2011, (201110), vol. 63, no. 10, Suppl. S, page S110 *
DHARMADHIKARI G ET AL, DIABETOLOGIA, & 45TH ANNUAL MEETING OF THE EUROPEAN-ASSOCIATION-FOR-THE-STUDY-OF-DIABETES; VIENNA, AUSTRIA; SEPTEMBER 30 -OCTOBER 02, 2009, (200909), vol. 52, no. Suppl. 1, ISSN 0012-186X, page S88 *
NGUYEN XUAN-HUNG ET AL, "Toso regulates the balance between apoptotic and nonapoptotic death receptor signaling by facilitating RIP1 ubiquitination", BLOOD, (201107), vol. 118, no. 3, pages 598 - 608 *
ZHANG L ET AL, "Alteration in the IL-2 signal peptide affects secretion of protein in vitro and in vivo", JOURNAL OF GENE MEDICINE, JOHN WILEY & SONS, INC, US, (20050301), vol. 7, no. 3, doi:10.1002/JGM.677, ISSN 1099-498X, pages 354 - 365 *

Also Published As

Publication number Publication date
CA2867444A1 (en) 2013-09-19
US20150299292A1 (en) 2015-10-22
US20130281356A1 (en) 2013-10-24
JP6462800B2 (ja) 2019-01-30
JP6744391B2 (ja) 2020-08-19
JP2015511599A (ja) 2015-04-20
JP6200437B2 (ja) 2017-09-20
EP2825191B1 (en) 2019-08-28
US10822388B2 (en) 2020-11-03
KR20150003197A (ko) 2015-01-08
JP2019054821A (ja) 2019-04-11
WO2013136193A3 (en) 2014-01-16
US9670265B2 (en) 2017-06-06
JP2018027951A (ja) 2018-02-22
AU2017272172A1 (en) 2017-12-21
AU2019204594B2 (en) 2021-05-06
IL234683B (en) 2020-02-27
US9321824B2 (en) 2016-04-26
AU2013234046A1 (en) 2014-10-09
US9624289B2 (en) 2017-04-18
CN104394880B (zh) 2020-08-28
CA2867444C (en) 2021-04-13
US9228006B2 (en) 2016-01-05
EP3626254A1 (en) 2020-03-25
KR102143887B1 (ko) 2020-08-12
WO2013136193A8 (en) 2014-05-08
US20150197551A1 (en) 2015-07-16
US20150139995A1 (en) 2015-05-21
CN104394880A (zh) 2015-03-04
EP2825191A2 (en) 2015-01-21
AU2017272172B2 (en) 2019-04-04
IL234683A0 (en) 2014-11-30
US20180016320A1 (en) 2018-01-18
AU2019204594A1 (en) 2019-07-18
WO2013136193A2 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
AU2019204594B2 (en) Methods and compositions for modulating toso activity
AU2015225867B2 (en) Methods and compositions for modifying the immune response
US20180201676A1 (en) Methods and compositions for modulating lilr proteins
HK1126961A (en) Use of complement pathway inhibitors to treat ocular diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired